BELARDINELLI LUIZ,GILLIES HUNTER CAMPBELL,LIANG FAQUAN,SHRYOCK JOHN,YANG SUYA
申请号：
NZ61001211
公开号：
NZ610012A
申请日:
2011.10.14
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
This disclosure relates to the use of a therapeutic effective amount of ambrisentan ((2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid - A) and tadalafil ((6R-trans)-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino[1&rsquo；,2&rsquo；:1,6] pyrido[3,4-b]indole-1,4-dione - B) in the manufacture of a medicament for treating pulmonary hypertension in a human patent, where the effect of the combination treatment is greater than the sum of the individual treatments of ambrisentan and tadalafil. The components are in a weight ratio of ambrisentan to tadalafil from about 1:1 to about 1:10. The disclosure also relates to the use of this combination for the treatment of endothelin-induced vasoconstriction, hypertension, myocardial infarction, angina pectoris, acute kidney failure, renal insufficiency, cerebral vasospasms, cerebral ischemia, subarachnoid haemorrhages, asthma, atherosclerosis, intravascular coagulation, restenosis after angioplasty, hypertension caused by ischemia or intoxication, kidney failure caused by ischemia or intoxication, Raynaud&rsquo；s syndrome and asthmatic airway conditions.
